Risk adjusted net present value: What is the current valuation of Novo Nordisk’s NN-9931?

NN-9931 is a recombinant peptide commercialized by Novo Nordisk, with a leading Phase III program in Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Backlash to affirmative action hits pioneering maternal health program for Black women

For Briana Jones, a young Black mother in San Francisco, a city program called the Abundant Birth Project has been a godsend.

November 24, 2023

Dollar General pulls mobile clinic mentions from website, partner no longer offering appointments

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

May 30, 2024

Nationwide Children’s Hospital pioneers new gene therapy for Duchenne muscular dystrophy

In a landmark moment for the Abigail Wexner Research Institute at Nationwide Children’s, a 5-year-old from Bellefontaine, Ohio, received the first dose of a recently

August 8, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.